Amendment No. 3 to Clinical and Commercial Supply Agreement Viral Vector ProductClinical and Commercial Supply Agreement • February 23rd, 2021 • Bluebird Bio, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 3 to the Clinical and Commercial Supply Agreement-Viral Vector Product (the “Amendment”) is made effective January 1, 2021, (“Amendment Effective Date”) by and between bluebird bio (Switzerland) GmbH (“Company”), and SAFC Carlsbad, Inc., a California corporation (“SAFC”). Company and SAFC may hereinafter be referred to as a Party or as the Parties. Capitalized terms used but not otherwise defined herein shall have the meanings given to such terms in the Agreement.
FIRST AMENDMENT TO CLINICAL AND COMMERCIAL SUPPLY AGREEMENTClinical and Commercial Supply Agreement • August 7th, 2020 • Aclaris Therapeutics, Inc. • Pharmaceutical preparations
This FIRST AMENDMENT TO CLINICAL AND COMMERCIAL SUPPLY AGREEMENT is entered into as of June 12, 2020 (this “First Amendment”), by and between Aclaris Therapeutics, Inc., a Delaware corporation (“Aclaris”), and PeroxyChem LLC, a Delaware limited liability company (“PeroxyChem”). Aclaris and PeroxyChem are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
CLINICAL AND COMMERCIAL SUPPLY AGREEMENTClinical and Commercial Supply Agreement • August 17th, 2015 • Aclaris Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS CLINICAL AND COMMERCIAL SUPPLY AGREEMENT (this “Agreement”), effective as of August 6, 2014 (“Effective Date”), by and between PeroxyChem, a Delaware corporation, with a principal place of business at 1735 Market Street, Philadelphia, Pennsylvania 19103 (“PeroxyChem”) and Aclaris Therapeutics, Inc., a Delaware corporation, with a principal place of business at 101 Lindenwood Drive, Suite 400, Malvern, Pennsylvania 19355 (“Aclaris”).
Clinical and Commercial Supply Agreement Viral Vector Product by and between bluebird bio, Inc. and SAFC Carlsbad, Inc. November 27, 2017Clinical and Commercial Supply Agreement • February 21st, 2019 • Bluebird Bio, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Clinical and Commercial Supply Agreement (this “Agreement”), executed as of November 27, 2017 and effective as of January 1, 2018 (the “Effective Date”), is entered into by and between:
Clinical and Commercial Supply Agreement Viral Vector Product by and between bluebird bio, Inc. and SAFC Carlsbad, Inc. November 27, 2017Clinical and Commercial Supply Agreement • August 1st, 2019 • Bluebird Bio, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Clinical and Commercial Supply Agreement (this “Agreement”), executed as of November 27, 2017 and effective as of January 1, 2018 (the “Effective Date”), is entered into by and between:
Amendment No. 5 to Clinical and Commercial Supply Agreement Viral Vector ProductClinical and Commercial Supply Agreement • November 7th, 2022 • Bluebird Bio, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 5 to the Clinical and Commercial Supply Agreement-Viral Vector Product (the “Amendment”) is made effective as of the date of last signature below, (“Amendment Effective Date”) by and between bluebird bio (Switzerland) GmbH (“Company”), and SAFC Carlsbad, Inc., (“SAFC”). Company and SAFC may hereinafter be referred to as a Party or as the Parties. Capitalized terms used but not otherwise defined herein shall have the meanings given to such terms in the Agreement.
Amendment No. 2 to Clinical and Commercial Supply Agreement Viral Vector ProductClinical and Commercial Supply Agreement • January 21st, 2020 • Bluebird Bio, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 2 to the Clinical and Commercial Supply Agreement-Viral Vector Product (the “Amendment”) is made on January 14, 2020, (“Amendment Effective Date”) by and between bluebird bio (Switzerland) GmbH (“Company”), and SAFC Carlsbad, Inc., a California corporation (“SAFC”). Company and SAFC may hereinafter be referred to as a Party or as the Parties. Capitalized terms used but not otherwise defined herein shall have the meanings given to such terms in the Agreement.
